» Articles » PMID: 19624560

Posttransplantation Hypomagnesemia and Its Relation with Immunosuppression As Predictors of New-onset Diabetes After Transplantation

Overview
Journal Am J Transplant
Publisher Elsevier
Specialty General Surgery
Date 2009 Jul 24
PMID 19624560
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

New-onset diabetes after transplantation (NODAT) is a frequent complication and has an impact on patient and graft survival. Hypomagnesemia is common in both renal transplant recipients and in diabetics. This study examines the relationship between hypomagnesemia, NODAT and the type of immunosuppression in renal transplant recipients. We conducted a retrospective single-center analysis (2002-2008) in order to assess NODAT the first year posttransplantation as defined by American Diabetes Association criteria. Serum magnesium (Mg) levels were defined as the median of all Mg levels registered during the first month posttransplantation. Patients with NODAT (N = 75; 29.5%) versus non-NODAT had lower Mg levels (p < 0.001). Patients with an Mg level < versus > or = 1.9 mg/dL showed a faster development of NODAT (log-rank p < 0.001). Mg levels were lower in patients on calcineurin inhibitors (CNI) versus no CNI patients (p < 0.001). Mg levels, albumin, BMI, triglycerides, posttransplantation hyperglycemia, tacrolimus levels and the use of sirolimus were predictors of NODAT in the multivariate analysis. Hypomagnesemia was an independent predictor of NODAT in renal transplant recipients. We confirm that the use of CNI is associated with NODAT, but, to a large extent, this effect seems attributable to the induction of hypomagnesemia. After adjustment for Mg, sirolimus was also associated with NODAT.

Citing Articles

Posttransplantation diabetes mellitus (PTDM): pharmacological aspects and genetic predispositions.

Chastagner D, Arnion H, Danthu C, Toure F, Picard N Pharmacogenomics. 2025; 25(16-18):707-718.

PMID: 40017426 PMC: 11901360. DOI: 10.1080/14622416.2025.2470613.


New Onset Diabetes After Organ Transplantation: Risk Factors, Treatment, and Consequences.

Popovic L, Bulum T Diagnostics (Basel). 2025; 15(3).

PMID: 39941214 PMC: 11816453. DOI: 10.3390/diagnostics15030284.


Hypomagnesemia, insulin secretion and action in patients without diabetes, 1 year after kidney transplantation.

Carlsen R, Asberg A, Svensson M, Birkeland K, Jorgensen H, Bressendorff I Front Med (Lausanne). 2025; 12:1492871.

PMID: 39911868 PMC: 11797832. DOI: 10.3389/fmed.2025.1492871.


Tacrolimus- and Mycophenolate-Mediated Toxicity: Clinical Considerations and Options in Management of Post-Transplant Patients.

Kaye A, Shah S, Johnson C, De Witt A, Thomassen A, Daniel C Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852117 PMC: 11763814. DOI: 10.3390/cimb47010002.


The Impact of Hypomagnesemia on the Long-Term Evolution After Kidney Transplantation.

Ratiu I, Moisa C, Marc L, Olariu N, Ratiu C, Bako G Nutrients. 2025; 17(1.

PMID: 39796484 PMC: 11722560. DOI: 10.3390/nu17010050.